nivolumab,girentuximab,cabozantinib,Ipilimumab,Sunitinib
heidelberg pharmaceuticals,esteve,prometheus,bms,Pfizer
['nivolumab', 'nivo', 'rcc,(-irccs),(-srcc),(-urcc)', 'girentuximab', 'cabozantinib']
phase 1b/2 study of combination 177lu girentuximab + cabozantinib and nivolumab in treatment na ve patients with advanced clear cell #rcc. presented by . #asco23 written coverage by &gt; 
Largest global online community of #urological medical professionals & patients. #bladdercancer #menshealth #prostatecancer #kidneycancer #Urology